Diamyd clinical trials

DiaPrecise, A Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® in individuals at risk for Type 1 diabetes carrying the HLA DR3-DQ2 haplotype

This study looks at a new treatment called Diamyd for people at risk of type 1 diabetes. Researchers want to see if giving Diamyd injections into a lymph node is safe and possible. This is an early-stage study to gather important information.